Abstract
Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 749-756 |
| Number of pages | 8 |
| Journal | Clinical Obstetrics and Gynecology |
| Volume | 56 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Obstetrics and Gynecology
Cite this
Controversies in osteoporosis management : Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents? / Gallagher, John Christopher G.; Tella, Sri Harsha.
In: Clinical Obstetrics and Gynecology, Vol. 56, No. 4, 12.2013, p. 749-756.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Controversies in osteoporosis management
T2 - Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?
AU - Gallagher, John Christopher G.
AU - Tella, Sri Harsha
PY - 2013/12
Y1 - 2013/12
N2 - Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.
AB - Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84887823989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887823989&partnerID=8YFLogxK
U2 - 10.1097/GRF.0b013e3182a982c2
DO - 10.1097/GRF.0b013e3182a982c2
M3 - Article
VL - 56
SP - 749
EP - 756
JO - Clinical Obstetrics and Gynecology
JF - Clinical Obstetrics and Gynecology
SN - 0009-9201
IS - 4
ER -